PT  - JOURNAL ARTICLE
AU  - Quentin J. Leclerc
AU  - Emily S. Nightingale
AU  - Sam Abbott
AU  - CMMID COVID-19 Working Group
AU  - Thibaut Jombart
TI  - Analysis of temporal trends in potential COVID-19 cases reported through NHS Pathways England
AID  - 10.1101/2020.05.16.20103820
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.16.20103820
4099  - http://medrxiv.org/content/early/2020/05/20/2020.05.16.20103820.short
4100  - http://medrxiv.org/content/early/2020/05/20/2020.05.16.20103820.full
AB  - The NHS Pathways triage system collates data on enquiries to 111 and 999 services in England. Since the 18th of March 2020, these data have been made publically available for potential COVID-19 symptoms self-reported by members of the public. Trends in such reports over time are likely to reflect behaviour of the ongoing epidemic within the wider community, potentially capturing valuable information across a broader severity profile of cases than hospital admission data. We present a fully reproducible analysis of temporal trends in NHS Pathways reports until 14th May 2020, nationally and regionally, and demonstrate that rates of growth/decline and effective reproduction number estimated from these data may be useful in monitoring transmission. This is a particularly pressing issue as lockdown restrictions begin to be lifted and evidence of disease resurgence must be constantly reassessed. We further assess the correlation between NHS Pathways reports and a publicly available NHS dataset of COVID-19-associated deaths in England, finding that enquiries to 111/999 were strongly associated with daily deaths reported 16 days later. Our results highlight the potential of NHS Pathways as the basis of an early warning system. However, this dataset relies on self-reported symptoms, which are at risk of being severely biased. Further detailed work is therefore necessary to investigate potential behavioural issues which might otherwise explain our conclusions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe following funding sources are acknowledged as providing funding for the named authors. This research was partly funded by the Bill & Melinda Gates Foundation (OPP1183986: ESN). This research was partly funded by the Global Challenges Research Fund (GCRF) project 'RECAP' managed through RCUK and ESRC (ES/P010873/1: TJ). This research was partly funded by the National Institute for Health Research (NIHR) using UK aid from the UK Government to support global health research. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the UK Department of Health and Social Care (Health Protection Research Unit for Modelling Methodology HPRU-2012-10096: TJ). UK MRC (LID DTP MR/N013638/1: QJL). Authors of this research receive funding from UK Public Health Rapid Support Team funded by the United Kingdom Department of Health and Social Care (TJ). Wellcome Trust (210758/Z/18/Z: SA). The following authors were part of the Centre for Mathematical Modelling of Infectious Disease 2019-nCoV working group. Each contributed in processing, cleaning and interpretation of data, interpreted findings, contributed to the manuscript, and approved the work for publication: Eleanor M Rees, Rosalind M Eggo, Matthew Quaife, Fiona Yueqian Sun, Carl A B Pearson, Kiesha Prem, James D Munday, Sophie R Meakin, Graham Medley, Kevin van Zandvoort, W John Edmunds, Alicia Rosello, Sebastian Funk, Kathleen O'Reilly, Billy J Quilty, Simon R Procter, Amy Gimma, Adam J Kucharski, Arminder K Deol, Jon C Emery, Nikos I Bosse, Hamish P Gibbs, David Simons, Stéphane Hué, Christopher I Jarvis, Petra Klepac, Yang Liu, Anna M Foss, Charlie Diamond, C Julian Villabona-Arenas, Akira Endo, Rein M G J Houben, Stefan Flasche, Timothy W Russell, Samuel Clifford, Gwenan M Knight, Joel Hellewell, Nicholas G. Davies, Katherine E. Atkins, Damien C Tully, Megan Auzenbergs, Mark Jit, Rachel Lowe. The following funding sources are acknowledged as providing funding for the working group authors. Alan Turing Institute (AE). BBSRC LIDP (BB/M009513/1: DS). This research was partly funded by the Bill & Melinda Gates Foundation (INV-003174: KP, MJ, YL; NTD Modelling Consortium OPP1184344: CABP, GM; OPP1180644: SRP; OPP1191821: KO'R, MA). DFID/Wellcome Trust (Epidemic Preparedness Coronavirus research programme 221303/Z/20/Z: CABP, KvZ). Elrha R2HC/UK DFID/Wellcome Trust/This research was partly funded by the National Institute for Health Research (NIHR) using UK aid from the UK Government to support global health research. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the UK Department of Health and Social Care (KvZ). ERC Starting Grant (#757688: CJVA, KEA; #757699: JCE, MQ, RMGJH). This project has received funding from the European Union's Horizon 2020 research and innovation programme - project EpiPose (101003688: KP, MJ, PK, WJE, YL). This research was partly funded by the Global Challenges Research Fund (GCRF) project 'RECAP' managed through RCUK and ESRC (ES/P010873/1: AG, CIJ). HDR UK (MR/S003975/1: RME). Nakajima Foundation (AE). NIHR (16/137/109: BJQ, CD, FYS, MJ, YL; Health Protection Research Unit for Modelling Methodology HPRU-2012-10096: NGD; PR-OD-1017-20002: AR). Royal Society (Dorothy Hodgkin Fellowship: RL; RP\EA\180004: PK). UK DHSC/UK Aid/NIHR (ITCRZ 03010: HPG). UK MRC (LID DTP MR/N013638/1: EMR; MC_PC 19065: RME; MR/P014658/1: GMK). Wellcome Trust (206250/Z/17/Z: AJK, TWR; 208812/Z/17/Z: SC, SFlasche; 210758/Z/18/Z: JDM, JH, NIB, SFunk, SRM). No funding (AKD, AMF, DCT, SH). Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll analyses were performed using the R software [13], and both the code and data are publicly available from https://github.com/qleclerc/nhs_pathways_report and distributed under the MIT license. https://github.com/qleclerc/nhs_pathways_report